Addex Therapeutics Files Form 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: Apr 17, 2025 · CIK: 1574232
Sentiment: neutral
Topics: filing, press-release, sec-report
TL;DR
Addex Therapeutics dropped a 6-K filing with a press release on 4/17/25 - check Exhibit 99.1 for deets.
AI Summary
On April 17, 2025, Addex Therapeutics Ltd. issued a press release, incorporated by reference into this Form 6-K filing. This press release is attached as Exhibit 99.1 and is being filed as part of their monthly report for April 2025.
Why It Matters
This filing indicates that Addex Therapeutics is providing an update or important information to the SEC through a press release, which could contain material news for investors.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain new financial data or significant operational updates.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- April 17, 2025 (date) — Date of press release and filing
- Exhibit 99.1 (document) — Attached press release
- Form F-3 (Registration No. 333-255089) (document) — Registration statement incorporated by reference
- Form S-8 (Registration No. 333-255124) (document) — Registration statement incorporated by reference
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release issued by Addex Therapeutics Ltd. on April 17, 2025, as required for foreign private issuers.
What is included as Exhibit 99.1 in this filing?
Exhibit 99.1 is a press release dated April 17, 2025, issued by Addex Therapeutics Ltd.
When was the press release mentioned in the filing issued?
The press release was issued on April 17, 2025.
Which registration statements are mentioned as incorporating this exhibit by reference?
The registration statement on Form F-3 (Registration No. 333-255089) and the registration statement on Form S-8 (Registration No. 333-255124) are mentioned.
What is the principal executive office address of Addex Therapeutics Ltd. as listed in the filing?
The principal executive office address is Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 17, 2025 regarding Addex Therapeutics Ltd. (ADXN).